In the emergency department, how should nalbuphine (inj. nalbin) be diluted in 10 mL of compatible fluid and administered as a 3 mL IV dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nalbuphine Administration Protocol in the Emergency Department

Your current ER practice of diluting nalbuphine (Nalbin) with Gravinate to 10 mL and administering 3 mL IV is not supported by standard guidelines and should be modified to follow FDA-approved protocols for safe and effective administration.

Recommended Administration Protocol

Based on FDA labeling, nalbuphine should be administered according to the following parameters 1:

Standard Dosing

  • Initial dose: 10 mg for a 70 kg individual
  • Routes: Subcutaneous, intramuscular, or intravenous
  • Frequency: Every 3-6 hours as necessary
  • Maximum single dose: 20 mg (in non-tolerant individuals)
  • Maximum daily dose: 160 mg

Proper Dilution and Administration

For IV administration, nalbuphine does NOT require routine dilution 1. The medication comes as a ready-to-use sterile solution at 20 mg/mL concentration 1.

If you choose to dilute for slower administration:

  • Use normal saline or compatible IV solution
  • Administer slowly over several minutes
  • Monitor for respiratory depression

Critical Safety Considerations

Your current 3 mL dose from a 10 mL dilution is problematic because:

  • The final concentration and actual nalbuphine dose delivered is unclear
  • Gravinate (dimenhydrinate) compatibility with nalbuphine is not established
  • Guidelines emphasize checking physicochemical compatibility when mixing opioids with other drugs parenterally 2

Alternative Evidence-Based Approach

Recent research supports co-administration strategies:

For patients prone to injection pain 3:

  • Mix equal volumes of nalbuphine (1 mL = 10 mg) with lidocaine (1 mL = 20 mg)
  • This undiluted combination significantly reduces injection pain (2.5% vs 30% incidence)
  • Administer at 0.33 mL/second

Standard practice should be:

  1. Draw up the appropriate dose based on patient weight (typically 0.1-0.2 mg/kg) 4
  2. Administer undiluted IV push slowly, OR
  3. If dilution preferred, use normal saline only (not Gravinate)
  4. Have naloxone immediately available 2

Common Pitfalls to Avoid

  • Do not mix nalbuphine with antiemetics without verified compatibility data
  • Do not use arbitrary dilution volumes that obscure actual dosing
  • Do not administer rapidly - this increases injection pain and adverse effects
  • Always calculate dose by patient weight, not fixed volumes

Monitoring Requirements

After administration 1:

  • Monitor respiratory rate closely for first 24-72 hours
  • Keep naloxone, resuscitation equipment, and oxygen readily available
  • Watch for respiratory depression (rate <8/min requires intervention)
  • Assess pain relief and titrate subsequent doses accordingly

Bottom line: Abandon the current Gravinate dilution practice. Use nalbuphine undiluted or diluted only with normal saline, dose by patient weight (0.1-0.2 mg/kg), and administer slowly IV with appropriate monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.